Nimesul

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nimesul

Property Description
Active ingredient Nimesulide
Form Tablets, Capsules, Granules, Topical Gels
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Primary Actions Analgesic, Anti-inflammatory, Antipyretic
Origin Synthetic organic compound

What is Nimesul and What Pharmacological Class Does it Belong To?

Nimesul is a medicinal preparation whose core component is Nimesulide, a substance classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Nimesulide is a synthetic organic compound recognized by its distinctive sulfonanilide structure, a chemical identity that sets it apart from common arylpropionic acid NSAIDs like ibuprofen. Pharmacological studies have supported Nimesulide's function as a cyclooxygenase-2 (COX-2) selective inhibitor, meaning it preferentially targets the COX-2 enzyme over COX-1, a key distinction clinically recognized for managing inflammation. This classification means the medication is designed to interact specifically with the body's pain and inflammation pathways and is primarily indicated for adults and adolescents.

Nimesulide’s High-Level Mechanism and General Purpose

The general purpose of Nimesul is to provide symptomatic relief by addressing the triad of acute pain, inflammation, and fever. It achieves this by inhibiting the activity of the COX-2 enzyme, thereby interrupting the synthesis of prostaglandins, which are the chemical mediators responsible for signaling these uncomfortable symptoms throughout the body. The medication is known for its rapid onset of action, allowing it to quickly deliver its combined analgesic (pain-relieving) and antipyretic (fever-reducing) effects. This action profile makes it a primary choice for instances of temporary discomfort, such as the pain associated with primary dysmenorrhoea or other acute inflammatory processes.

Forms and Composition: Single Ingredient and Delivery Types

Nimesul is designed as a single active ingredient product (monotherapy) and is available by prescription-only for systemic forms in many regions. It is manufactured in several distinct pharmaceutical preparations, including common dosage form(s) like tablets, capsules, and granules for oral suspension intended for oral use, alongside specialized localized forms like topical gels or sprays. The base/vehicle used varies to ensure efficient delivery of the Nimesulide compound, utilizing standard pharmaceutical excipients for ingested forms and specific hydroalcoholic bases for effective topical administration.

What side effects are possible with Nimesul?

Possible Side Effects and Safety Information

The safety profile for Nimesul is strictly documented by government regulatory agencies and involves a defined range of potential adverse reactions, particularly concerning the liver and gastrointestinal system.

Serious Safety Risks and Contraindications

The most critical safety concern is the risk of hepatotoxicity (serious liver injury), including rare cases of fulminant hepatitis which may be fatal or require liver transplantation. Treatment must be stopped immediately if signs of liver damage or gastrointestinal bleeding occur.

For safety, the medicine is contraindicated (should not be used) in several patient groups, including children under 12 years of age and patients with pre-existing hepatic impairment (liver disease), severe renal impairment (kidney disease), or active gastrointestinal ulceration/bleeding. The concurrent use of other potentially hepatotoxic drugs is also contraindicated.

Adverse Reaction Frequencies

Adverse reactions are classified by frequency as reported in regulatory documents:

  • Common: Diarrhea, nausea, vomiting, and minor elevation of liver enzyme levels.
  • Uncommon: Gastritis, dyspepsia, dizziness, vertigo, hypertension, and edema (swelling).
  • Rare/Very Rare: Serious reactions include Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) (severe skin reactions), anaphylaxis, and acute renal failure.

Safety Restrictions

Regulatory documentation imposes a strict maximum treatment duration of 15 days for systemic formulations. This limitation is in place to help minimize the risk of serious, long-term adverse effects, particularly liver injury. Caution is also advised when Nimesul is used with anticoagulants due to an increased risk of bleeding.

Overdose and Emergency Response

Overdose scope

Documented overdose presentations: Overdose presentations documented in official regulatory sources typically include gastrointestinal effects such as epigastric pain, nausea, vomiting, and diarrhea. Central nervous system effects such as drowsiness and lethargy have also been reported in clinical contexts.

Physiological systems affected (as stated in label): The primary physiological systems affected in severe overdose are the hepatic system (potential for acute liver failure), the renal system (potential for acute renal failure), and the gastrointestinal system (risk of bleeding, ulceration, or perforation).

Dose-related or exposure-related factors (if applicable): The risk of severe effects appears greater with a larger acute ingestion. The elderly and patients with pre-existing severe renal or hepatic impairment are noted to face an increased risk of toxicity and severity in an overdose scenario.

Overdose classifications (high-level)

Severity classification (as defined in official documents): The officially documented outcomes range from common but serious effects to life-threatening events such as acute liver failure, which may require transplantation, or severe gastrointestinal perforation.

Regulatory basis (EMA / FDA / etc.): Management is defined by a non-specific protocol, as no specific antidote is known for Nimesulide overdose.

Overdose-context constraints (as defined in official documents): Treatment is symptomatic and supportive. Hospital monitoring of liver enzyme levels and renal function may be required following an acute ingestion.

Resulting overdose structure

Official overdose statements:

  • Seek immediate medical attention when symptoms suggestive of acute liver injury develop, including anorexia, persistent vomiting, abdominal pain, persistent tiredness, or dark urine.
  • Treatment must be discontinued immediately if gastrointestinal bleeding or ulceration is suspected.
  • Management is limited to supportive care, and monitoring of renal and hepatic function is often mandated.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents establish the overdose profile primarily through the risk of life-threatening hepatic and renal failure, alongside significant gastrointestinal and CNS manifestations. This risk dictates the explicit requirement to seek immediate medical attention when specific, labeled symptoms that suggest organ injury develop, positioning the documented manifestations as direct triggers for emergency response.

Therapeutic Uses of Nimesul

Nimesulide is relevant in contexts involving heightened systemic burden and symptoms related to acute pain and inflammatory processes.

Clinical relevance focuses on the short-term symptomatic relief of acute pain, painful osteoarthritis, and primary dysmenorrhoea in adults and adolescents. It is relevant for managing symptoms that interfere with daily comfort, and may assist with maintaining functional stability during difficult episodes.

The medicine is commonly used to help with symptoms related to acute pain, the supportive management of discomfort during painful osteoarthritis flare-ups, and applied in addressing challenging symptoms related to primary dysmenorrhoea (menstrual cramps). It is also often used when symptoms intensify following minor procedures, supporting the patient by easing distress after dental surgery.

Clinical Benefits

The medication helps support the patient during difficult episodes by easing distress and may assist with maintaining functional stability when symptoms are more noticeable. It may contribute to improved comfort during periods of heightened symptoms, relevant in contexts involving inflammatory or irritative states that follow minor musculoskeletal injuries.


Quick Fact: Relief for Acute Symptomatic Pain

The medicine is relevant when supportive symptom management is appropriate for acute, sudden-onset pain characterized as mild to moderate. It is also applied in addressing challenging symptoms associated with fever.

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Nimesulide?

Nimesulide eligibility is strictly defined by regulatory authorities based on age, physiological status, and pre-existing medical conditions. Use is formally authorized for adults and adolescents 12 years and older. A critical regulatory criterion mandates that the medicine must only be used as a second-line treatment and for a maximum duration of 15 days.

Nimesulide is formally contraindicated and must not be used in patients under 12 years of age. Absolute non-eligibility applies to patients with any degree of hepatic impairment or severe renal impairment (creatinine clearance < 30 ml/min). Contraindications extend to those with active gastrointestinal ulcers or bleeding, severe heart failure, or a history of hypersensitivity to NSAIDs. Physiologically, use is prohibited during the third trimester of pregnancy and in breastfeeding women; it is not recommended for women attempting to conceive. Use in elderly patients requires special caution and clinical monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Nimesulide's interaction profile based on its metabolic pathway effects and additive pharmacodynamic risks. Nimesulide is documented as an inhibitor of the CYP2C9 enzyme, a pharmacokinetic action that may increase the plasma concentrations of co-administered medicines that are CYP2C9 substrates. This interaction profile dictates specific constraints and required monitoring for several classes of drugs.

Documented Interaction Restrictions

Classification Interacting Agents / Classes Restriction Summary (Official Statement)
Contraindicated / Avoid Other potentially hepatotoxic substances; Alcohol abuse Must be avoided due to the increased risk of hepatic reactions.
Not Recommended Other NSAIDs; Anticoagulants Combined use is not recommended due to increased risk of gastrointestinal (GI) bleeding or complications.

Pharmacokinetic and Pharmacodynamic Effects

Co-administration with Lithium reduces its clearance, resulting in elevated plasma levels and potential toxicity; monitoring is required. The combination with Methotrexate requires caution if administered less than 24 hours before or after Nimesulide, as it may increase Methotrexate's serum levels. Pharmacodynamically, Nimesulide may reduce the efficacy of Diuretics, ACE Inhibitors, and Angiotensin II Antagonists (AIIA), with a documented risk of deterioration of renal function in susceptible renal or cardiac patients. Increased bleeding risk also exists with Anti-platelet agents and SSRIs.

Mechanism of Action

Targeted Enzyme Modulation

This domain focuses on the drug's primary action as a selective inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. By blocking COX-2, the drug interrupts the production of pro-inflammatory mediators, which modifies signaling patterns that contribute to nociceptor hypersensitivity and limits local fluid accumulation.


Antioxidant Activity and ROS Neutralization

The mechanism is further defined by its activity as an antioxidant, neutralizing destructive Reactive Oxygen Species (ROS) that accumulate at sites of heightened physiological response. This action contributes to cellular component stabilization and influences the rate of reactive oxygen species-driven biochemical processes.


Modulation of Tissue-Degrading Enzymes

A final mechanistic layer involves the drug's influence on enzymes called Matrix Metalloproteinases (MMPs), which are involved in the degradation of the extracellular matrix. Inhibition of MMP activity reduces the rate of enzymatic degradation of the extracellular matrix, influencing the structure of connective tissues.

Dosage and Administration Information

How Nimesul is Used: Official Administration Guidelines

Nimesulide is prescribed under strict protocols that govern its administration, dosage, frequency, and duration. This approach ensures the medicine is utilized precisely according to specified guidelines for symptomatic relief.


Core Administration Scope

Systemic Nimesulide is available in oral forms, such as 100 mg tablets or granules for suspension, designed for ingestion. Topical formulations, typically gels, are available for localized administration to the skin. The standard adult dosing regimen is 100 mg administered twice daily (B.I.D.). This dosing pattern imposes a strict maximum daily intake of 200 mg for systemic use, which must not be exceeded.


Procedural and Time Constraints

For oral forms, the medicine must be consumed after a meal (post-prandial administration) and taken with sufficient water to ensure proper use. A crucial constraint is the mandatory limit on duration: systemic treatment is authorized for the shortest possible duration required to manage acute symptoms, and in no case should it exceed 15 consecutive days.

Population-Specific Rules are also defined. The use of Nimesulide is explicitly contraindicated in children under 12 years of age. For older adults, emphasis is placed on starting and maintaining treatment at the lowest effective dose for the minimal necessary duration. Specific dose reductions or avoidance are also mandated for patients with established renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Acute Pain and Analgesic Effects

Clinical research has evaluated Compound X for the management of acute pain, including post-operative and trauma-related pain. Studies examined patient-reported pain scores following administration; some reports indicated changes within 30 minutes, suggesting a fast onset of action.

  • Dose-Response Trials: Early phase trials investigated the relationship between different Compound X dosages and the magnitude of analgesic response. These findings provided context for the selection of doses evaluated in later-stage randomized controlled trials (RCTs).
  • Combination Therapy: One key meta-analysis assessed whether the combination of Compound X and a standard analgesic was associated with changes in headache severity over 24 hours. Research has also explored this combination in managing dental pain.

Anti-inflammatory Activity

Research has investigated the anti-inflammatory activity of Compound X. Studies explored its interactions with prostaglandin pathways. In vivo models examined its effect on specific inflammatory biomarkers.

  • Chronic Conditions: Comparative trials have explored potential differences in outcomes between Compound X and other non-steroidal anti-inflammatory drugs (NSAIDs) for chronic conditions like back pain and osteoarthritis. These trials primarily focused on functional improvement scores and patient quality of life measures.

Pediatric and Safety Considerations

Studies have investigated Compound X for fever reduction in pediatric populations; pediatric studies primarily focused on children over the age of two. In comparative studies, Compound X was evaluated for potential differences in antipyretic effect compared to other common treatments.

  • Drug Interactions: Research has examined the co-administration of Compound X and alcohol due to concerns regarding potential liver effects. Clinical data suggested the potential for increased enzyme markers in a subset of study participants, a risk recognized across the NSAID class.

Further Research Directions

The available evidence summarizes findings on Compound X's profile in various acute pain and inflammatory conditions. Research has not reported extensive long-term safety data or use in all chronic pain populations.

Frequently Asked Questions (FAQ)

Common questions about Nimesul (FAQ)


Q: Is Nimesul a standard non-steroidal anti-inflammatory drug (NSAID) like ibuprofen or diclofenac?

A: Yes, Nimesulide is classified as an NSAID. However, official information notes that it is specifically a COX-2 selective inhibitor, which is a type of NSAID that differs from non-selective NSAIDs like ibuprofen or diclofenac in its primary mechanism of action.


Q: How quickly should I expect Nimesul to start working for acute pain?

A: Studies and official product information indicate that Nimesulide has a rapid onset of action. Clinical data indicates that pain relief may begin for some patients as quickly as 15 minutes after taking the medicine.


Q: What are the most commonly reported side effects of Nimesul?

A: According to official regulatory documents, the most common side effects reported are diarrhea, nausea, and vomiting. Minor, often temporary, elevations of liver enzyme levels in the blood are also frequently reported.


Q: Can Nimesul cause stomach upset, nausea, or diarrhea?

A: Yes, regulatory documents list nausea, vomiting, and diarrhea as common adverse reactions. Less common, but still reported, are symptoms of stomach upset like gastritis or dyspepsia.


Q: Does Nimesul carry a risk of gastrointestinal bleeding or ulcers?

A: Official warnings state that, like all NSAIDs, Nimesulide carries a risk of serious gastrointestinal events. Gastrointestinal bleeding, ulceration, and perforation have been reported, and these complications may be severe or fatal.


Q: Can Nimesul affect the function of my kidneys?

A: Official information indicates that Nimesulide may cause a deterioration of renal (kidney) function in susceptible patients, such as those with pre-existing conditions. In rare cases, acute renal failure has been reported as a serious adverse reaction.


Q: Can Nimesul be used by women experiencing painful menstrual cramps (dysmenorrhea)?

A: Yes, Nimesulide is formally indicated in many regions for the treatment of acute pain, which includes symptomatic relief for conditions like primary dysmenorrhoea (painful menstrual cramps).


Q: What are the considerations for taking Nimesul while breastfeeding?

A: Official regulatory documents state that Nimesulide is prohibited and contraindicated for use in women who are breastfeeding. This restriction is in place because the passage into breast milk and the potential effects on the infant are not fully established.


Q: Does Nimesul interact with blood thinners or anti-coagulant medicines?

A: Yes, co-administration with blood thinners (anticoagulants) is not recommended according to official guidelines. Nimesulide can increase the effect of these medications, which significantly raises the risk of bleeding.


Q: Does Nimesul interact with diuretics or 'water pills'?

A: Yes, official warnings state that Nimesulide may reduce the effectiveness of diuretics (water pills) and certain blood pressure medicines. In patients who are predisposed, this interaction can also increase the risk of a decline in kidney function.


Q: Are there any known interactions between Nimesul and alcohol consumption?

A: Official product information states that co-exposure to alcohol abuse is contraindicated (must be avoided). This restriction is in place due to the increased potential risk of serious liver reactions.


Q: Can Nimesul cause a skin rash or itching, and is that a serious side effect?

A: Skin reactions like rash or itching (pruritus) can occur. Very rare, but extremely serious, skin reactions such as Stevens-Johnson Syndrome (SJS) have been reported and require immediate medical attention.


Q: Is Nimesul used to treat the pain associated with a toothache or dental procedures?

A: Clinical research has explored its use and official documents indicate it is approved for the treatment of acute pain, which can include pain related to dental procedures.


Q: Is Nimesul available in different forms (e.g., tablet, gel, suspension)?

A: Yes, Nimesulide is manufactured in multiple forms. These include oral forms such as tablets and granules for suspension, as well as forms for topical use like gels.


Q: What is the typical duration of Nimesul's pain-relieving effects?

A: Official pharmacological data indicates that Nimesulide has a relatively short half-life of approximately 1.8 to 4.7 hours. This short duration of action is reflected in the requirement for regular dosing.


Q: Is Nimesul intended for short-term use only, or can it be taken long-term?

A: Regulatory guidance strictly limits the duration of use. Nimesulide is only authorized for the shortest possible duration necessary to treat acute symptoms and must not exceed 15 consecutive days of treatment.


Q: Is it normal to feel a bit dizzy or drowsy after taking Nimesul?

A: No, while adverse reactions like dizziness and vertigo (a spinning sensation) are reported as uncommon side effects, they are not considered a normal effect. If these effects occur, it is important to be aware of how they may affect daily activities.


Q: Is there a concern about Nimesul affecting liver function?

A: Yes, official regulatory warnings highlight the risk of serious liver injury (hepatotoxicity), which includes rare, fatal cases. Treatment is restricted in duration to help minimize this risk.


Q: What are the long-term effects of taking Nimesul occasionally for headaches?

A: Nimesulide is only approved for acute pain and its use is strictly limited to a maximum of 15 days. Due to this restriction and safety concerns, official bodies have not reported extensive long-term safety data for the drug.


Q: Does Nimesul affect female fertility or make it harder to conceive?

A: Regulatory documents state that Nimesulide is not recommended for women who are actively trying to conceive. Like other NSAIDs, it may temporarily impair female fertility, but this effect is generally reversible when the medicine is stopped.


Q: If I have mild, chronic pain, is Nimesul a suitable option for long-term management?

A: No, official indications specify that Nimesulide is only approved for the symptomatic relief of acute pain. Due to safety restrictions, its use is strictly limited to a maximum duration of 15 consecutive days, making it unsuitable for long-term chronic pain management.


Q: If I notice my urine is dark or I feel unusually tired, could it be related to Nimesul?

A: Official warnings state that symptoms such as dark urine, unusual fatigue, or abdominal pain may be compatible with liver injury. The appearance of these signs requires prompt medical attention and stopping the medication.


Q: Does Nimesul affect my eyesight or concentration?

A: Adverse reactions such as dizziness, drowsiness (somnolence), and visual disturbances have been reported. If these side effects occur, they may impair your concentration.


Q: What is the research evidence for Nimesul's effectiveness in treating painful osteoarthritis?

A: Nimesulide is officially indicated for the symptomatic treatment of painful osteoarthritis. Clinical research, alongside official regulatory approval, supports its indication for this use.


Q: Do other medicines for depression or mood disorders interact with Nimesul?

A: Yes, official documents warn that Nimesulide can interact with certain medicines for depression, specifically Selective Serotonin Reuptake Inhibitors (SSRIs). This combination may increase the risk of gastrointestinal bleeding.


Q: If I take Nimesul with food, does it reduce the risk of stomach irritation?

A: The official administration guidelines mandate that the medicine must be consumed after a meal (post-prandial administration) with water. This procedure is a common practice for NSAIDs to ensure proper use and to help reduce potential gastrointestinal side effects.


Q: What are the symptoms of an overdose of Nimesul?

A: Symptoms of acute overdose are primarily lethargy, drowsiness, nausea, vomiting, and pain in the upper abdomen. More serious effects can include gastrointestinal bleeding and acute liver failure.


Q: If I have a history of a reaction to any NSAID, am I also likely to react to Nimesul?

A: Nimesulide is contraindicated if you have a history of hypersensitivity reactions to aspirin (acetylsalicylic acid) or other non-steroidal anti-inflammatory drugs (NSAIDs). This is due to the potential for cross-reactivity between NSAID medicines.


Q: Is it safe to drive or operate machinery after taking Nimesul?

A: Official warnings state that adverse effects like dizziness or drowsiness (somnolence) have been reported with Nimesulide. If these adverse effects occur, activities requiring mental alertness, such as driving or operating machinery, should be avoided.


How should Nimesul be stored and disposed of?

How to Store and Dispose of Nimesulide

Storage Conditions

Nimesulide must be stored in a cool, dry, well-ventilated place, away from heat and sources of ignition, and kept from direct sunlight. The container must remain tightly closed and stored in its original packaging to ensure the product's stability. Due to the compound's heat-sensitive nature, it should not be stored near incompatible substances.

Child-Safety Storage

The medication must be stored locked up and kept out of the sight and reach of children to prevent accidental ingestion, as mandated by official labeling requirements.

Disposal Instructions

Unused or expired Nimesulide must be disposed of in accordance with local, regional, and national regulations. To protect the environment, the product should not be released into the environment or disposed of in public waters or drains. Contents and containers must be taken to an approved waste disposal plant.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nimesul found in:

A-Z Index: